Early Atherosclerosis in HIV Infected Subjects on Suppressive Antiretroviral Treatment: Role of Osteoprotegerin

Table 1

Clinical characteristics.

	HIV−; (FS < 10%)	HIV+	HIV−; (FS > 10%)
Age (M ± SD)	48±9	53±8.8	55±8
Sex	21 M, 0 F	35 M, 0 F	20 M, 0 F
Smoke status (n, %)
no	15 (71%)	20 (57.1%)	6 (30%)
yes	6 (29%)	15 (42.9%)	14 (70%)
CD4+ (mmc) (M ± SD)	770±221	570±341.2	689±197
CD4+ % (M ± SD)	36±9.3	17.3±7.6	33.6±8.7
CD4+ (mmc) nadir (M ± SD)	—	287.7±253.4	—
CD4+ % nadir (M ± SD)	—	12.9±8.7	—
HIV-RNA zenith (cp/mL) (M ± SD)	—	257376.5±346884.8	—
HIV-RNA (cp/mL)	<37	<37	<37
Lipid-lowering therapy
no	21 (100%)	35 (100%)	12 (60%)
yes	0	0	8 (40%)
Systolic blood pressure (mmHg)	114.8±17.5	117.3±15.5	125.8±18.5
Diastolic blood pressure (mmHg)	81.8±11.4	77.3±12.5	88.3±20.5
Triglycerides (mg/dL) (M ± SD)	113.6±31	178.8±90.2	198.5±82
Cholesterol Total (mg/dL) (M ± SD)	150.3±35.8	200.7±51.7	266.3±48.7
Cholesterol HDL (mg/dL) (M ± SD)	53.2±16.7	41.8±13.6	39.8±12.6
Cholesterol LDL (mg/dL) (M ± SD)	102.5±32.4	133.3±47.2	172.7±42.4
Body mass index (kg/m^2) (M ± SD)	18.7±2.5	20.7±2.4	21.7±2.3
Framingham score	3.2±2.1%	4.1±3.2%	13.4±5.4%

FS: Framingham score; M: mean; SD: standard deviation; HDL: high density lipoprotein; LDL: low density lipoprotein.